Loading
companiesCompany
Alixia
Alixia is developing drugs that act on the supporting cells and inflammation around a tumour as well as the cancer cells, to stop cancers from becoming resistant.
Overview
Alixia develops small molecules that disrupt metabolic and inflammatory signalling shared by cancer cells and the quasi-cancerous stromal and immune cells in the tumour microenvironment, on the thesis that hitting several cell types at once produces more durable responses and fewer resistance escape routes. The company is tagged oncology in the YC directory and remains active with a very small team; programmes are preclinical and no sourced financing rounds are recorded.
Headquarters
San Francisco, CA, US
Funding
All startupsStartupYC W22
Investors
Type
Stage
Startup · Y Combinator Winter 2022
Website
Similar pages
- CompanyVelorum Therapeutics
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.
- CompanyAltay Therapeutics
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.
- CompanyHarmonic Discovery
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyReverie Labs
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.
- CompanyResistanceBio (Viosera Therapeutics)
Shares Y Combinator and the tag yc.